French Society in Atherosclerosis/French-Speaking Association for the study of diabetes and metabolic diseases (SFC/ALFEDIAM) recommendations on the management of diabetic patients seen by cardiologists;Recommandations SFC/ALFEDIAM sur la prise en charge du patient diabétique vu par le cardiologue

Diabetes and Metabolism

Volumn 30, Issue 3 II, 2004, Pages

  Charbonnel, B ^a   Bouhanick, B ^a   Le Feuvre, C ^a   Bauduceau, Bernard ^a   Danchin, Nicolas ^a   Gautier, Jean Fraņois ^a   Grimaldi, André ^a   Henry, Patrick ^a   Paillard, François ^a   Pallo, Danièle ^a   Piot, Christophe ^a   Sabouret, Pierre ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CAPTOPRIL; DIURETIC AGENT; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOR; HEMOGLOBIN A1C; INDAPAMIDE; INSULIN; LOSARTAN; METFORMIN; METFORMIN EMBONATE; MIGLITOL; NITRENDIPINE; ORAL ANTIDIABETIC AGENT; PERINDOPRIL; PIOGLITAZONE; RAMIPRIL; REPAGLINIDE; ROSIGLITAZONE; STATINE DERIVATIVE; SULFANILAMIDE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

BLOOD PRESSURE REGULATION; CALORIC RESTRICTION; CARDIOLOGY; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC DIET; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DIET THERAPY; ELECTROCARDIOGRAM; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPERTENSION; INSULIN TREATMENT; LIPID METABOLISM; MEDICAL SOCIETY; METABOLIC DISORDER; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COUNSELING; PATIENT EDUCATION; PHYSICAL ACTIVITY; REVIEW; RISK FACTOR; SECONDARY PREVENTION; TREATMENT CONTRAINDICATION;

CARDIOLOGY; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; QUALITY ASSURANCE, HEALTH CARE;

EID: 3142689543     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. nd ed. Bethesda, Md: National Institute of Health, 1995, 429-48. NIH publication 95-1468.
2. Saydah SH, Eberhardt MS, Loria CM, Brancati FL. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol, 2002, 156, 714-9.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior history of myocardial infarction. N Eng J Med, 1998, 339, 229-34.
4. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort study. B Med J, 2002, 324, 939-42.
5. Sprafka JM, Burke GI, Folsom AR, McGovern PG, Hahn LP. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival: the Minnesota Heart Survey. Diabetes Care, 1991, 14, 537-43.
6. Suivi du patient diabétique de type 2, à l'exclusion du suivi des complications: recommandations de l'ANAES. Diabetes Metab, 1999, 25, 1-64.
7. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet, 2002, 359, 2140-4.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults. Executive summary of the third report of the National Cholesterol Education program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults (adult treatment panal III). JAMA. 2001, 285, 2486-97.
9. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow up report on the diagnosis of Diabetes Mellitus. Diabetes Care, 2003, 26, 3160-7.
10. Richard LD, Sultan A, Daures JP, Vannereau D, Parer-Richard C. Diagnosis of diabetes mellitus and intermediate glucose abnomalities in obese patients based on ADA (1997) and WHO (1985) criteria. Diabetes Metab, 2002, 19, 292-9.
11. The Expert Committee on the Diagnosis and classification of diabetes mellitus. Diabetes Care, 1997, 20, 1183-97.
12. Girard J. Fondements physiopathologiques du diabète de type 2. Revue du Prat, 1999, 49, 22-9.
13. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia, 2003, 46, 3-19.
14. American Diabetes Association. Screening for diabetes. Diabetes Care, 2003, 26, S21-4.
15. Abedin M, McGuire DK. Don't miss the opportunity: diagnosing diabetes. Am Heart J, 2003, 145, 195-7.
16. Taubert G, Winkelmann BR, Qchleiffer T, Marz W, Gok R, Klein B, Schneider S, Boehm BO. Prevalence, predictors and consequences of unrecognized diabetes mellitus in 3,266 patients scheduled for coronary angiography. Am J Heart, 2003, 145, 285-91.
17. Heilbronn LK, Noakes M, Clifton PM. Effects of energy restriction, weight loss, and diet composition on plasma lipids, and glucose in patients with type 2 diabetes. Diabetes Care, 1999, 22, 889-95.
18. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercice on glycemic control and body mass in type 2 diabetes mellitus. JAMA, 2001, 286, 1218-27.
19. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002, 346, 393-403.
20. 1c in the diabetes control and complications trial. Diabetes Care, 2002, 25, 275-8.
21. UK Prospective Diabetes Study (UKPDS). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet, 1998, 352, 854-65.
22. Stang M, Wysowski DK, Buttler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care, 1999, 22, 925-7.
23. Traitement médicamenteux du diabète de type 2. Recommandations AFSSAPS. Diabetes Metab, 1999, 25, 1-79.
24. Stratégie de prise en charge du patient diabétique de type 2 à l'exclusion de la prise en charge des complications. Recommandations de l'ANAES. Diabetes Metab, 2000, 26 (Suppl 5), 1-96.
25. Evans JMM, Newton RW, Ruta DA, McDonald TM, Stevenson RJ, Morris AD. Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. BMJ, 1999, 319, 83-6.
26. Blonde L, Ginsberg BH, Horn S, Hirsch IB, James B, Mulcamy K, Nettles A, Smout R, Wright H. Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes (letter). Diabetes Care, 2002, 25, 245.
27. Schwedes U, Siebolds M, Mertes G, for the SMBG Group. Meal-related structured self-monitoring of blood glucose. Effect on diabetes control in non-insulin treated type 2 diabetic patients. Diabetes Care, 2002, 25, 1928-32.
28. Guerci B, Drouin P, Grange V, Bougnères P, Fontaine P, Kerlan V, Passa P, Thivolet C, Vialettes B, Charbonnel B for the ASIA Group. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Diabetes Metab, 2003, 29, 587-94.
29. UK Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control and sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837-53.
30. UKPDS UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 1998, 317, 703-13.
31. Berlowitz DR, Ash AS, Hickey EC, Glickman M, Friedman R, Kader B. Hypertension management in patients with diabetes. The need for more aggressive therapy. Diabetes Care, 2003, 26, 355-9.
32. Adler AI, Stratton IM, Neil AW, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. On behalf of the UK Prospective Diabetes Study group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. B Med J, 2000, 321, 412-9.
33. Hansson L, Zanchetti A, Carruthers Sg, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 1998, 351, 1755-62.
34. UK Prospective Diabetes Study Group: Efficacity of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ, 1998, 317, 713-20.
35. Heart Outcomes Prevention Evaluation (HOPE) study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and the MICRO-HOPE study. Lancet, 2000, 355, 253-9.
36. Dahlof B, Dereveux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H for the LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359, 995-1003.
37. PROGRESS collaborative group. Randomised trial of a perindopril based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet, 2001, 358, 1033-41.
38. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA, 2002, 287, 2570-81.
39. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, the Scandinavian Simvastatin Survival study (4S) group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Group. Diabetes Care, 1997, 20, 614-20.
40. Heart Protection Study Collaborative group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360, 7-22.
41. Bloomfield Rubins H, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J for the Veterans Affairs High-density lipoprotein cholesterol Intervention Trial Study group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med, 1999, 341, 410-8.
42. Collaborative group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet, 2001, 357, 89-95.
43. US Preventive service Task Force. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. Ann Intern Med, 2002, 136, 161-72.
44. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996, 348, 1329-39.
45. Mizock BA. Alterations of fuel metabolism in critical illness: hyperglycemia. Best Pract Res Clin Endocrinol, 2001, 15, 533-51.
46. Sala J, Masia R, Gonzales de Molina FJ, Fernandez-Real JM, Gil M, Bosch D, Ricart W, Senti M, Marrugat J; REGICOR investigators. Short-term mortality of myocardial infarction in patients with diabetes or hyperglycaemia during admission. J Epidemiol Community Health, 2002, 56, 707-12.
47. Malmberg K. for the DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) study group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ, 1997, 314, 1512-5.
48. van den Berghe G, Wouters P, Weekers F, Vermaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Eng J Med, 2001, 345, 1359-67.
49. Dandona P, Aljada A, Bandyopadbyay A. The potential therapeutic role of insulin in acute myocardial infarction in patients admitted to intensive care and in those with unspecified hyperglycemia. Diabetes Care, 2003, 26, 516-9.
50. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg, 1999, 67, 352-62.
51. Birck R, Krzossok S, Markowetz F, Schnülle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet, 2003, 362, 598-603.
52. Thomsen HS, Morcos SK, ESUR Contrast Media Safety Committee. Contrast media and metformine: guidelines to disminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. Eur Radiol, 1999, 9, 738-40.
53. Diaz-sandoval JL, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol, 2002, 89,356-8.
54. Caputo C, Dokko JH, Durham JH, Pahlavan M, Keltz J, Dutka P, Marzo K, Zaharakis T, Fishbane S. A randomized control trial of N-acetyl cysteine to prevent contrast nephropathy following coronary angiography. Am J Kidney Dis, 2002, 39. A 14 abstract.
55. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, Pinkett T, Ghali JK, Wilson AC. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trial and registry. Am J Cardiol, 1996, 77, 1017-20.
56. Blickle JF, Attali JR, Barrou Z, Brocker P, de Rekeneire N, Verny C, Leutenegger M. Le diabète du sujet âgé. Rapport des experts de l'ALFEDIAM. Diabetes Metab, 1999, 25, 84-93.
57. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med, 1997, 157, 1681-6.
58. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care, 2003, 26, 510-3.
59. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. for the collaborative study group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001, 345, 851-60.
60. Brenner BM, Cooper ME, de Zeew D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S the RENAAL study investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001, 861-9.
61. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. for the Irbesartan in patients with type 2 diabetes and microalbuminuria study group. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med, 2001, 345, 870-8.
62. Palmer BE Renal dysfunction complicating the treatment of hypertension. N Eng J Med, 2002, 347, 1256-61.
63. Zanchetti A, Hansson L, Dalhof B, Julius S, Menard J, Warnold I, Wedel H, on behalf of the HOT study group. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertension, 2002, 20, 2301-7.
64. Adler AL, Stevens RJ, Neil A, Stratton IM, Boulton AJM, Holman RR, for the UK Prospective study. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care, 2002, 25, 894-9.
65. Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care, 2003, 26, 491-4.
66. De Sèze J, Leys D. Les accidents vasculaires céré braux chez le diabétique. Sang Thrombose Vaisseaux, 1997, 9, 235-40.
67. Davis TME, Millns H, Stratton IM, Holman RR, Turner RC, for the UK Prospective Study Group. Risk factors for stroke in type 2 diabetes. United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med, 1999, 159, 1097-103.
68. Williams LS, Rotish J, Qi R, Fineberg N, Espay A, Bruno A, Fineberg SE, Tierney WR. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 2002, 59, 67-71.
69. Megherbi SE, Milan C, Minier D, Couvreur G, Osseby GV, Tilling K, Carlo A, Inzitari D, Wolfe CD, Moreau T, Giroud M, European BIOMED Study of Stroke Care Group. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. Stroke, 2003, 34, 688-94.
70. Staessen JA, Fagard R, Thijs L, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet, 1997, 350, 757-64.
71. Hansson L, Lindholm LH, Niskanen L, et al., for the Captopril Prevention Project (CAPP) study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP). Lancet, 1999, 353, 611-6.
72. Hansson L, Lindholm LH, Ekbom T, et al., for the STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet, 1999, 354, 1751-6. (STOP-2).
73. Hansson L, Hedner T, Lund-Johansen P, et al., for the NORDIL study group. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet, 2000, 356, 359-65.
74. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet, 2000, 356, 366-72.
75. Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension, 2001, 38, e28-e32.
76. Lindhom LH, Ibsen HI, Dahlof B, Devereux RB, Beevers G, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359, 1004-10.
77. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2002, 288, 2981-97.